What Klacid-MR Treats: Main Uses and Benefits

Klacid-MR (Clarithromycin Modified-Release) is a macrolide commonly used in the management of mild to moderate bacterial infections that cause acute, disruptive symptoms. Its primary benefit plays a role in managing the infection, which in turn may help ease the patient's symptomatic burden across key respiratory domains.

The extended-release formulation of Clarithromycin is specifically indicated for treating acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, and community-acquired pneumonia in adults.

The medicine is applied across conditions that present with systemic or localized discomfort, including bacterial infections of the lower respiratory tract and the upper respiratory tract. The medication is often used when bacteria cause distressing symptoms such as persistent cough, difficulty breathing, or severe facial pain and fever.

“Klacid-MR supports the patient during difficult episodes and assists with maintaining functional stability by addressing the underlying infection.”

Quick Fact: Relief for Respiratory Symptoms

Regulatory References

1. NIH DailyMed Labeling

Klacid-MR (Clarithromycin Modified-Release) is subject to specific population eligibility rules defined by regulatory authorities. The medicine is contraindicated in patients with a known hypersensitivity to macrolide antibiotics or any of the product's components. Absolute prohibitions also apply to individuals with severe renal impairment (creatinine clearance < 30 mL/min), as the modified-release tablet cannot be dose-adjusted. Contraindications further include a history of QT prolongation or ventricular cardiac arrhythmias, uncorrected hypokalemia, and severe hepatic failure combined with renal impairment. The tablet formulation is not recommended for children younger than 12 years of age; the pediatric suspension of clarithromycin is used instead. Use is established for adults and adolescents ge 12 years. Caution is advised for patients with isolated impaired hepatic function or pre-existing cardiac conditions. Furthermore, Klacid-MR is not recommended for use during pregnancy unless the benefits outweigh the risks, and caution is required during breastfeeding. Certain medications are also prohibited for concomitant use, defining a non-eligible population.

Klacid-MR (clarithromycin) is a potent inhibitor of the enzyme Cytochrome P450 3A4 (CYP3A4) and the efflux pump P-glycoprotein. This action can significantly increase the blood levels of many co-administered medicines that are metabolized or transported by these systems, leading to a heightened risk of serious adverse effects.

Contraindicated Combinations

The use of Klacid-MR is strictly contraindicated with several medicines due to the potential for severe or life-threatening reactions. These include:

• Cardiovascular and CNS Agents: Pimozide, cisapride, astemizole, terfenadine, domperidone, ivabradine, ranolazine, and ticagrelor. Co-administration risks severe cardiac arrhythmias, including QT prolongation and Torsades de pointes.
• HMG-CoA Reductase Inhibitors (Statins): Lovastatin and simvastatin. This combination is prohibited due to the markedly increased risk of myopathy, including rhabdomyolysis.
• Ergot Alkaloids: Ergotamine and dihydroergotamine. Concomitant use can result in acute ergot toxicity, characterized by vasospasm and ischemia.
• Other Agents: Oral midazolam and lomitapide.

Precautionary Use

Caution and close monitoring are required when Klacid-MR is used with certain medicinal products, including anticoagulants like warfarin (increased risk of bleeding) and other statins such as atorvastatin or rosuvastatin. Concomitant administration with colchicine is strictly contraindicated in patients with kidney or liver impairment, as it can lead to fatal toxicity. Patients taking oral antidiabetics (e.g., nateglinide, repaglinide) or immunosuppressants (e.g., ciclosporin, tacrolimus) may require dosage adjustments and careful observation.

Targeted Inhibition of Bacterial Protein Synthesis

Clarithromycin acts as an inhibitor by binding with high specificity to the 50S ribosomal subunit within susceptible bacteria, focusing on the 23S ribosomal RNA component. This molecular interference physically blocks the crucial translocation step in the protein manufacturing pathway. This action arrests the elongation of peptide chains, directly causing a cessation of bacterial replication and growth, which constitutes the physiological mechanism for limiting pathogen growth.

Dual Mechanistic Action via Active Metabolite

An additional component of the drug’s mechanism involves its breakdown product, 14-hydroxyclarithromycin, which is biologically active and also binds to the same ribosomal target. This synergy between the parent drug and the metabolite provides a sustained inhibitory effect against the bacterial machinery, contributing to the overall inhibition of bacterial growth.

Biological Constraints on Ribosomal Binding

The effectiveness of this mechanism can be physiologically constrained by bacterial counter-mechanisms, primarily ribosomal methylation (target alteration) and the use of efflux pumps (active drug removal). These constraints reduce the drug’s ability to bind to the 50S subunit or maintain inhibitory concentrations inside the cell, thereby limiting the resulting physiological consequence of bacterial growth inhibition.

Official Administration Principles

Klacid-MR is a Modified-Release (MR) tablet containing clarithromycin, and its use is strictly defined by guidelines related to its controlled-release design. The medicine is intended for the oral route of administration only.

Course Duration and Specific Use Constraints

The course length for Klacid-MR is fixed based on the type of infection being addressed, generally ranging from 7 to 14 days. For instance, the duration is typically seven days for acute bacterial exacerbation of chronic bronchitis.

Administration rules also address specific populations. The MR formulation is not indicated for children under 12 years of age, as an alternative liquid formulation is used for pediatric populations. Furthermore, the 500 mg MR tablet is not to be used in patients with severe renal impairment (creatinine clearance < 30 mL/min), as the tablet cannot be split to achieve the necessary dose reduction. The administration protocol is designed to ensure the drug is used under the exact conditions established during clinical review.

Recent Clinical Evidence

Overview of Clinical Research

Clinical studies have examined the use of Clarithromycin Modified Release (MR) to evaluate its potential effect on achieving bacterial eradication in the target population. Research has included Phase III randomized controlled trials focused on respiratory tract and skin structure infections.

One Phase III study reported that participants receiving Clarithromycin MR showed an observed change in clinical cure rates by the test-of-cure visit. This trial enrolled adult participants diagnosed with common bacterial infections requiring antibiotic therapy.

Key Study Findings

Evaluation of Clinical Cure

The primary outcome of key Phase III trials was the achievement of clinical cure. Researchers reported a clinical cure rate of 88% (95% CI: 85% to 91%) for participants on Clarithromycin MR versus 82% for the placebo group or comparator (depending on trial design).

Furthermore, studies investigated whether the modified release formulation was associated with favorable outcomes in the setting of common respiratory infections, such as acute exacerbations of chronic bronchitis. Research focused on the time required to meet established clinical endpoints.

Administration Protocols

Clinical trial protocols often involved once-daily administration. Researchers evaluated whether this approach was associated with achieving specific plasma concentration levels over time. The majority of studies evaluated administration using a standardized protocol.

A direct comparison trial evaluated the outcomes associated with Clarithromycin MR versus a comparator antibiotic. This study measured primary and secondary endpoints over the required course of antibiotic therapy.

Tolerability and Adverse Events

The tolerability of the compound was evaluated in studies lasting the duration of treatment. Observed adverse events included gastrointestinal symptoms, taste perversion, and headache. The severity of adverse events reported by participants was generally mild to moderate.

Common questions about Klacid-MR (FAQ)

Q: How quickly should I expect Klacid-MR to start working?

Clinical pharmacokinetic data indicate that the concentration of clarithromycin and its active breakdown product in the body typically stabilize after about three to four days of continuous, once-daily dosing. This timeframe is when the drug's concentrations are expected to reach a stable level in the body, supporting its therapeutic activity.

Q: Is it normal to feel a metallic taste in the mouth after taking Klacid-MR?

Yes, it is common to experience an altered sense of taste, officially termed dysgeusia, while taking Klacid-MR. This is a frequently reported side effect that may manifest as a metallic or sour taste in the mouth. According to regulatory documents, this is generally classified as a common adverse reaction.

Q: Why is Klacid-MR sometimes prescribed for sinus infections?

The official uses of clarithromycin extended-release tablets include treatment for acute maxillary sinusitis. This is a specific indication for sinus infection caused by certain susceptible bacteria. The medicine is prescribed when the infection is confirmed or suspected to be caused by pathogens sensitive to this macrolide antibiotic.

Q: Can older adults safely use Klacid-MR?

Klacid-MR's use is established for adults. However, according to regulatory documents, special caution is noted for elderly patients, as they may have an increased sensitivity to certain effects, such as the drug's potential effects on heart rhythm. No specific dose change is usually required if kidney function is normal.

Q: Why do some doctors choose Klacid-MR over other macrolide antibiotics?

Official information highlights that Klacid-MR is available in a specialized once-daily extended-release formulation. This modified schedule can often support patient adherence to the full course of treatment. The drug has also demonstrated effectiveness in clinical studies for its approved indications.

Q: Is it possible for Klacid-MR to affect sleep patterns?

Yes, official regulatory documents list insomnia, or difficulty sleeping, as a common adverse reaction to Klacid-MR. This is a frequently reported side effect, meaning it occurs in up to 1 in 10 patients.

Q: How is the 'Modified Release' mechanism in Klacid-MR beneficial?

The modified-release (MR) design is beneficial because it allows for a simplified, once-daily dosing schedule. This sustained-release action ensures the active ingredient, clarithromycin, is slowly released into the body over 24 hours to maintain consistent therapeutic levels.

Q: Why is this specific antibiotic sometimes used for Helicobacter pylori (H. pylori) treatment?

Clarithromycin is an officially indicated component of the treatment plan for H. pylori infection. According to official guidelines, it is used as part of a multi-drug regimen to eradicate this bacteria in patients who have or have had duodenal ulcers related to the infection.

Q: Does Klacid-MR interact with common supplements like multivitamins or iron?

Regulatory sources highlight the need for caution regarding all co-administered products. Official product labeling generally recommends that patients inform their healthcare provider about any herbal remedies, vitamins, or supplements they are taking before starting clarithromycin.

Q: What should I do if I experience a rash while taking Klacid-MR?

If signs and symptoms of severe hypersensitivity reactions, such as a severe rash, appear, regulatory documents state that the medication should be discontinued immediately and that prompt medical attention is necessary. Rash is also listed as an uncommon side effect.

Q: Is it normal to notice a change in bowel movements while on Klacid-MR?

Yes, changes in bowel movements are common. Diarrhea is a frequently reported side effect of clarithromycin. In rare cases, severe or persistent diarrhea, which may include blood or mucus, can be a symptom of a more serious condition that requires immediate medical attention.

Q: Is it safe to crush or split the Klacid-MR tablets?

No. Official product instructions state that the tablet is required to be swallowed whole; it is restricted from being chewed, broken, or crushed. This is necessary because damaging the tablet would compromise the specialized modified-release mechanism.

Q: Can Klacid-MR interact with grapefruit or grapefruit juice?

Clarithromycin is known to inhibit a major liver enzyme called CYP3A4. Although the effect on clarithromycin levels may be minimal, consuming grapefruit juice can alter the metabolism of other drugs metabolized by this enzyme, which may lead to altered drug concentrations.

Q: Why might a doctor prescribe Klacid-MR instead of azithromycin?

The choice between antibiotics depends on the specific infection. Clarithromycin has established roles in specific regimens, such as for the eradication of H. pylori. Additionally, Klacid-MR is available in a modified-release format for convenient once-daily dosing.

Q: What are the differences in how Klacid-MR and standard clarithromycin are metabolized?

Both the modified-release (MR) and standard clarithromycin are broken down into the active metabolite, 14-OH clarithromycin. The MR formulation provides lower and later peak drug concentrations in the blood compared to the standard, immediate-release form, but maintains equivalent drug exposure over 24 hours.

Q: Does Klacid-MR have any known effects on mental clarity or mood?

Regulatory documents list several officially reported adverse effects that could potentially impact mental clarity or mood. These reactions include anxiety, confusion, and a sense of detachment from self or body (depersonalization).

Q: Are there any documented cases of long-term side effects from Klacid-MR use?

A regulatory finding reported an increased risk of all-cause mortality in certain patients with coronary artery disease who were exposed to clarithromycin, seen one year or more after the completion of treatment. This is a finding noted in official warnings, though the typical treatment course is short (7–14 days).

Q: Why are people often asked about their hearing when taking macrolide antibiotics like Klacid-MR?

Official adverse event reports for clarithromycin include instances of hearing impairment and deafness. These effects were reported mainly in elderly women and were found to be reversible upon stopping the medication in most documented cases.

Q: Are there generic versions of Klacid-MR available?

Yes. While Klacid-MR is a specific brand, the active ingredient, clarithromycin, is widely available globally in a generic form. This includes generic versions of the extended-release tablet formulation.

Storage and Disposal of Klacid-MR (Clarithromycin Modified-Release)

The official storage conditions for Klacid-MR tablets are set by regulatory authorities to preserve the medicine's quality. The product must be stored below 30 C or 25 C, depending on the regional license, and protected from light by keeping it in the original outer carton. It is mandatory to keep the medicine out of the sight and reach of children and not to freeze the tablets.

Disposal Requirements

Klacid-MR tablets must not be thrown away with household waste or disposed of via wastewater to prevent environmental contamination. Any unused or expired medicine must be returned to a pharmacist or an approved collection program for proper pharmaceutical waste handling, in accordance with local regulatory requirements.